Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily (Q46648555)

From Wikidata

Jump to navigation Jump to search

scientific article published in August 2005

Language	Label	Description	Also known as
English	Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily	scientific article published in August 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Antonio Alcaraz Asensio

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

1

object named as

Mark Emberton

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

author name string

Mostafa Elhilali

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Haim Matzkin

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Niels Harving

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Jeroen van Moorselaar

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Rudolf Hartung

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Guy Vallancien

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Alf-One Study Group

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

66

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

316-322

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Benign prostatic hyperplasia: a progressive disease of aging men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Acute urinary retention in men: an age old problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Guideline for the primary care management of male lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

EAU Guidelines on benign prostatic hyperplasia (BPH).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.024

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.UROLOGY.2005.03.024

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16098361

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46648555&oldid=2124263392"